Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 138

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Acute myeloid leukaemia+1

Not yet recruiting

Safety and feasibility study of CARCIK‑CD123/33 cell therapy in adult and pediatric patients with relapsed or refractory AML and BPDCN

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Fondazione IRCCS San Gerardo Dei Tintori

Triple negative breast cancer

Not yet recruiting

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Institut Paoli-Calmettes

Plasma cell myeloma

Not yet recruiting

Teclistamab drug combination versus daratumumab and lenalidomide in MRD‑positive multiple myeloma patients after stem cell transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Polish Myeloma Consortium

Adenocarcinoma gastric+3

Not yet recruiting

Study of immune response and biomarkers in patients with metastatic solid tumors treated with BMS-986340 and nivolumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Humanitas Mirasole S.p.A.

Gastric cancer

Not yet recruiting

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Non-small cell lung cancer+1

Not yet recruiting

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Gastric cancer+1

Not yet recruiting

Capecitabine drug combination in perioperative treatment for patients with gastric and esophageal cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Colorectal adenocarcinoma

Not yet recruiting

Safety, Dose‑Finding and Feasibility Study of CD30/CEA CART in Patients with Liver Metastases from CEA‑Positive Colorectal Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Universitaetsklinikum Regensburg AöR

B precursor type acute leukaemia

Not yet recruiting

Phase II study of autologous enriched T‑cell therapy expressing CD19 and CD22 CARs in Philadelphia‑negative B‑precursor ALL patients with measurable residual disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22
  • Sponsor:Goethe University Frankfurt

Squamous cell carcinoma of the oral cavity+1

Not yet recruiting

Study of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Amsterdam UMC Stichting

Breast cancer

Not yet recruiting

Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin Sodium
  • Sponsor:University Hospital Of Clermont-Ferrand

Malignant pleural effusion

Not yet recruiting

Effect of Intrathoracic Aerosol Cisplatin and Doxorubicin on Malignant Pleural Effusion in Patients with Unresectable Pleural Carcinomatosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hospices Civils De Lyon

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.